Study of Novel Treatment Combinations in Patients With Lung Cancer (NCT05633667)
A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC) who have not been treated before. Substudy-02 will compare the different novel combination versus standard of care in participants with cancer that has progressed after receiving previous treatment for metastatic NSCLC. Substudy-03 will compare the different novel combinations versus standard of care in participants with resectable stage II-III NSCLC. The primary objectives of this study are: Substudy-01 and Substudy-02: To evaluate the objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Substudy-03: To evaluate the efficacy of treatment combinations based on complete pathological response (pCR) rate.
Who can join: Review the eligibility criteria below.
Location: Arizona Oncology Associates,Substudy-02 — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (89 Sites)
Showing the first 25 of 89 sites.
- Arizona Oncology Associates,Substudy-02 — Tucson, Arizona
- Fort Wayne Medical Oncology and Hematology, Inc.,Substudy-03 — Fort Wayne, Indiana
- Baptist Health Lexington,Substudy-03 — Lexington, Kentucky
- Washington University School of Medicine - Siteman Cancer Center,Substudy-01 — St Louis, Missouri
- Washington University School of Medicine - Siteman Cancer Center,Substudy-02 — St Louis, Missouri
- Washington University School of Medicine - Siteman Cancer Center,Substudy-03 — St Louis, Missouri
- Washington University School of Medicine - Siteman Cancer Center — St Louis, Missouri
- Oncology Hematology Care Clinical Trials, LLC,Substudy-01 — Cincinnati, Ohio
- Oncology Hematology Care Clinical Trials, LLC,Substudy-02 — Cincinnati, Ohio
- Oncology Associates of Oregon, PC,Substudy-01 — Eugene, Oregon
- Oncology Associates of Oregon, PC,Substudy-02 — Eugene, Oregon
- Fundação Pio XII - Hospital de Amor,Substudy-01 — Barretos,
- Centro Gaúcho Integrado de Oncologia Hematologia, Ensino e Pesquisa Ltda./Hospital Mãe de Deus,Substudy-03 — Porto Alegre,
- Hospital Mae de Deus,Substudy-01 — Porto Alegre,
- Hospital Mae de Deus — Porto Alegre,
- Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-01 — Porto Alegre,
- Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-03 — Porto Alegre,
- BP-A Beneficencia Portuguesa De Sao Paulo,Substudy-01 — São Paulo,
- Fundação Antonio Prudente - Hospital do Câncer AC Camargo,Substudy-01 — São Paulo,
- Fundação Antonio Prudente/A.C. Camargo Cancer Center,Substudy-03 — São Paulo,
- Real e Benemérita Associação Portuguesa de Beneficência/Hospital Beneficência Portuguesa de São Paulo (Hospital BP),Substudy-03 — São Paulo,
- Queen Mary Hospital,Substudy-01 — Hong Kong,
- Queen Mary Hospital,Substudy-02 — Hong Kong,
- Queen Elizabeth Hospital,Substudy-01 — Hong Kong,
- Queen Elizabeth Hospital,Substudy-02 — Hong Kong,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Cancer
- Implementation Strategies for Monitoring Adherence in Real Time — Philadelphia, Pennsylvania
- Early Detection of Lung Cancer — Nashville, Tennessee
- Improving Utilization of Lung Cancer Screening in Underserved PA Populations — Allentown, Pennsylvania
- Effect of Pulmonary Rehabilitation on Surgical Outcomes in the Cancer Setting — Houston, Texas
- Testing the Engaged Approach to Lung Cancer Screening — Denver, Colorado
- Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer — Boston, Massachusetts
Explore by condition: All Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.